# A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)

> **NCT00546286** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 170 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** dorzolamide hydrochloride (+) timolol maleate
- **DRUG:** Comparator: dorzolamide HCl/timolol maleate + prostaglandin

## Key facts

- **NCT ID:** NCT00546286
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-31
- **Primary completion:** 2007-08-23
- **Final completion:** 2007-08-23
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546286, "A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00546286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*